GlassScriptPhysician profile
Liawaty Ho
NPI 1558576686
$16,891.17
in general payments reported to CMS, 2019-2025
67 companies · $4,091 in 2025
The $4,091 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,692 · 2020: $281 · 2021: $498 · 2022: $752 · 2023: $4,423 · 2024: $4,154 · 2025: $4,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,488.51 |
| Education | $179.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,675.89 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $1,665.31 | 2019-2025 | |
| Amgen INC. | $1,136.56 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| Exelixis INC. | $1,015.62 | 2019-2025 | Cabometyx |
| Pfizer INC. | $995.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $838.48 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $688.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Sobi, INC | $585.11 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $561.48 | 2019-2024 | Opdivo, Eliquis, Opdualag |
| Gilead Sciences, INC. | $499.84 | 2019-2025 | Trodelvy |
| Incyte Corporation | $498.23 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Janssen Biotech, INC. | $478.24 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Beigene USA, INC. | $477.41 | 2023-2025 | Brukinsa |
| Genzyme Corporation | $390.50 | 2019-2024 | |
| Astellas Pharma US INC | $389.27 | 2019-2024 | Padcev, Xospata, Xtandi |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $389.14 | 2019-2025 | Tecentriq, Perjeta, Alecensa |
| Ipsen Biopharmaceuticals, INC | $369.98 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Servier Pharmaceuticals LLC | $327.41 | 2019-2025 | Voranigo |
| Seagen INC. | $323.25 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Emd Serono, INC. | $283.13 | 2019-2025 | Bavencio, Tepmetko |
| Regeneron Healthcare Solutions, INC. | $273.56 | 2019-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $190.12 | 2022-2025 | Xpovio |
| Lilly USA, LLC | $188.94 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Array Biopharma INC | $178.58 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Aurobindo Pharma USA, INC. | $177.68 | 2019 | |
| Glaxosmithkline, LLC. | $175.04 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Sirtex Medical INC | $164.19 | 2023-2025 | Sir-Spheres Microspheres |
| Celgene Corporation | $149.46 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $138.63 | 2019-2025 | Fruzaqla, Iclusig |
| Sumitomo Pharma America, INC. | $131.78 | 2023-2025 | Orgovyx |
| Beone Medicines USA, INC. | $113.27 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $110.19 | 2022-2025 | |
| Eisai INC. | $105.77 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $101.25 | 2022-2024 | Odomzo, Yonsa |
| Abbvie INC. | $79.67 | 2023-2024 | |
| Stemline Therapeutics INC. | $77.49 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $68.97 | 2019-2023 | Nerlynx |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Coherus Oncology, INC. | $64.33 | 2024-2025 | Loqtorzi |
| Genmab U.S., INC. | $56.60 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $54.36 | 2019-2023 | Ultomiris |
| Geron Corporation | $51.84 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $50.91 | 2019 | |
| Mirati Therapeutics, INC. | $42.94 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $40.64 | 2023-2025 | Pyrukynd |
| Morphosys, US INC. | $40.49 | 2023 | Monjuvi |
| Octapharma USA, INC. | $39.86 | 2019 | |
| Aveo Pharmaceuticals, INC. | $34.65 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $34.42 | 2019-2023 | Imbruvica |
| Kite Pharma, INC. | $25.95 | 2022 | |
| Amag Pharmaceuticals, INC. | $24.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.31 | 2023 | Gilotrif |
| Myriad Women'S Health, INC. | $23.02 | 2023 | Precisetumor |
| Immunogen, INC. | $22.90 | 2023 | Elahere |
| Caris Mpi, INC. | $22.51 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $22.04 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $18.69 | 2019 | |
| Verastem, INC. | $18.39 | 2019 | |
| Accord Healthcare, INC. | $17.12 | 2023 | |
| Forte Bio-Pharma LLC | $15.17 | 2023 | Prolate, Nalocet |
| Rigel Pharmaceuticals, INC. | $14.97 | 2023 | Rezlidhia, Tavalisse |
| Foundation Medicine, INC. | $14.24 | 2019 | |
| Eusa Pharma (US) LLC | $13.22 | 2019 | |
| Taiho Oncology, INC. | $13.10 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liawaty Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.